Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, JULY 23, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF LARIMAR THERAPEUTICS, INC. ("LARIMAR" OR THE "COMPANY") (NASDAQ: LRMR). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF LARIMAR THERAPEUTICS, INC. - LRMR

NEW YORK, JULY 21, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF LARIMAR THERAPEUTICS, INC. (LARIMAR OR THE COMPANY) (NASDAQ: LRMR). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK , JULY 16, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF LARIMAR THERAPEUTICS, INC. ("LARIMAR" OR THE "COMPANY") (NASDAQ: LRMR). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JULY 14, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF LARIMAR THERAPEUTICS, INC. (LARIMAR OR THE COMPANY) (NASDAQ: LRMR). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK, JULY 9, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF LARIMAR THERAPEUTICS, INC. ("LARIMAR" OR THE "COMPANY") (NASDAQ: LRMR). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JULY 07, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF LARIMAR THERAPEUTICS, INC. (LARIMAR OR THE COMPANY) (NASDAQ: LRMR). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

NEW YORK, JULY 1, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF LARIMAR THERAPEUTICS, INC. ("LARIMAR" OR THE "COMPANY") (NASDAQ: LRMR). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

BALA CYNWYD, PA., JUNE 29, 2026 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES, TODAY ANNOUNCED IT HAS SUBMITTED THE FIRST MODULE OF ITS ROLLING BIOLOGICS LICENSE APPLICATION (BLA) SUBMISSION TO THE FOOD AND DRUG ADMINISTRATION (FDA) FOR ACCELERATED APPROVAL OF NOMLABOFUSP; THE REMAINING MODULES ARE EXPECTED TO BE SUBMITTED IN THE SECOND HALF OF 2026. THE SUBMISSION WAS MADE AFTER OBTAINING FDA MEETING MINUTES OF A TYPE B MULTIDISCIPLINARY PRE-BLA MEETING. THE COMPANY ALSO ANNOUNCED POSITIVE DATA FROM THE ONGOING LONG-TERM OPEN LABEL (OL) STUDY EVALUATING DAILY SUBCUTANEOUS INJECTIONS OF NOMLABOFUSP IN ADOLESCENT AND ADULT PATIENTS WITH FRIEDREICH'S ATAXIA (FA). FA IS A RARE, PROGRESSIVE, AND FATAL NEUROLOGICAL DISEASE WITH NO APPROVED DISEASE MODIFYING THERAPIES THAT ADDRESS THE ROOT CAUSE OF THE DISEASE.

LARIMAR THERAPEUTICS REPORTS POSITIVE OPEN LABEL DATA AND SUBMISSION OF FIRST MODULE OF ROLLING BLA FOR ACCELERATED APPROVAL OF NOMLABOFUSP FOR FRIEDREICH'S ATAXIA

BALA CYNWYD, PA., JUNE 26, 2026 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES, TODAY ANNOUNCED THAT THE COMPANY WILL HOST AN INVESTOR EVENT TO DISCUSS UPDATES FOR THE COMPANY'S NOMLABOFUSP CLINICAL DEVELOPMENT PROGRAM INCLUDING A REGULATORY UPDATE AND DATA FROM THE ONGOING LONG-TERM OPEN LABEL STUDY FOR THE TREATMENT OF FRIEDREICH'S ATAXIA ON MONDAY, JUNE 29, 2026 AT 7:45 AM ET.

LARIMAR THERAPEUTICS ANNOUNCES INVESTOR EVENT ON THE NOMLABOFUSP PROGRAM FOR FRIEDREICH'S ATAXIA

INTENDING TO INITIATE ROLLING BLA SEEKING ACCELERATED APPROVAL WITH SUBMISSION OF NONCLINICAL AND CLINICAL MODULES IN JUNE 2026; SUBMISSION OF THE FINAL MODULES INCLUDING THE CMC MODULE EXPECTED IN SECOND HALF OF 2026 CROSS-SPECIES NONCLINICAL FINDINGS THAT SUPPORT SKIN FRATAXIN LEVELS AS A SURROGATE ENDPOINT FOR NOMLABOFUSP PROGRAM PUBLISHED IN PEER-REVIEWED JOURNAL TOPLINE OPEN LABEL STUDY DATA TO SUPPORT BLA SUBMISSION EXPECTED IN Q2 2026 $200.4 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2026, WITH PROJECTED CASH RUNWAY INTO THE SECOND QUARTER OF 2027 BALA CYNWYD, PA., MAY 14, 2026 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES,TODAY REPORTED ITS FIRST QUARTER 2026 OPERATING AND FINANCIAL RESULTS.

Larimar Therapeutics, Inc.

LRMR

Price

Financial Reports

No items found.

Press Releases

Larimar Therapeutics, Inc.

LRMR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

LRMR